Loading...
Loading...
HCWB| Name | Value |
|---|---|
| Revenues | 0.4M |
| Cost of Revenue | 1.0M |
| Gross Profit | -0.6M |
| Operating Expense | 14.7M |
| Operating I/L | -3.2M |
| Other Income/Expense | -0.2M |
| Interest Income | 0.0M |
| Pretax | -3.4M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -3.4M |
HCW Biologics Inc. is a preclinical stage biopharmaceutical company specializing in the discovery and development of novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, an injectable immunotherapeutic for various cancers and pulmonary fibrosis, and HCW9302 for auto-immune and metabolic diseases. Additionally, it is developing HCW9201, a cell-based therapy in Phase II clinical trials for relapsed/refractory acute myeloid leukemia, and HCW9206 for acute myeloid leukemia treatment.
